Inicio
Autor Kenny Mauricio Gálvez Cárdenas
|
Comentario :
Médico Internista Hematólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (45)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaReal World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry / Kenny Mauricio Gálvez Cárdenas ; Munevar, Isabel ; Idrobo, Henry ; Armando Mantilla, William ; Domingo Saavedra Ramírez
Título : Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor Fecha de publicación : 2025 Títulos uniformes : Clinical Lymphoma, Myeloma and Leukemia Idioma : Inglés (eng) Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor . - 2025.
Obra : Clinical Lymphoma, Myeloma and Leukemia
Idioma : Inglés (eng)
Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002322 AC-2025-005 Archivo digital Producción Científica Artículos científicos Disponible
Título : Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 Years or older in Colombia: a RENEHOC-PETHEMA study Tipo de documento : documento electrónico Autores : Laura María Díaz Correa, Autor ; Kenny Mauricio Gálvez Cárdenas, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of Hematology Idioma : Inglés (eng) Palabras clave : Acute Myeloid Leukemia Treatment Outcomes Elderly Patients Overall Survival Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range: 60–98), 55% were men, 61% had an ECOG?2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% of patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), non-intensive chemotherapy (non-IC) low dose cytarabine based chemotherapy (12.6%), hypomethylating agents (HMA, with/without venetoclax) (35.3%), and supportive care (15.2%). Median overall survival (OS) was 8.2 months (10.6 months after IC, 8.8 after non-IC, 8.9 months after HMA, 8.2 months after HMA plus venetoclax, and 1.9 months with supportive care). OS was 35.2% at 1 year and 5.6% at 5 years (13.7% treated with IC). Only 1.5% of patients were transplanted in frontline. Leukemia-free survival (LFS) was 17.6 month, with 67.6% survival at 1 year and 27.3% at 5 years. Among patients treated with IC, the 5-year LFS was 41.3%, and 0% for non-IC. A shift from IC to HMA plus venetoclax regimens was observed after venetoclax marketing. This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients. Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello Polo, Luis A. Salazar, Angela M. Peña, María Lucrecia Luna González, Diana Marcela Cuervo-Lozada, Guillermo E. Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, Lina M. Gaviria, Mario Ernesto Correa Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza Morales, Juan Carlos Serrano Casas, Francisco Jaramillo, Rigoberto Gomez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez Veiga, David Martínez Cuadrón, Pau Montesinos. Referencia : Annals of Hematology on January 16th, 2025 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0. Derechos de uso : CC BY En línea : https://www.researchsquare.com/article/rs-5119261/v1 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 Years or older in Colombia: a RENEHOC-PETHEMA study [documento electrónico] / Laura María Díaz Correa, Autor ; Kenny Mauricio Gálvez Cárdenas, Autor . - 2024.
Obra : Annals of Hematology
Idioma : Inglés (eng)
Palabras clave : Acute Myeloid Leukemia Treatment Outcomes Elderly Patients Overall Survival Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range: 60–98), 55% were men, 61% had an ECOG?2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% of patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), non-intensive chemotherapy (non-IC) low dose cytarabine based chemotherapy (12.6%), hypomethylating agents (HMA, with/without venetoclax) (35.3%), and supportive care (15.2%). Median overall survival (OS) was 8.2 months (10.6 months after IC, 8.8 after non-IC, 8.9 months after HMA, 8.2 months after HMA plus venetoclax, and 1.9 months with supportive care). OS was 35.2% at 1 year and 5.6% at 5 years (13.7% treated with IC). Only 1.5% of patients were transplanted in frontline. Leukemia-free survival (LFS) was 17.6 month, with 67.6% survival at 1 year and 27.3% at 5 years. Among patients treated with IC, the 5-year LFS was 41.3%, and 0% for non-IC. A shift from IC to HMA plus venetoclax regimens was observed after venetoclax marketing. This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients. Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello Polo, Luis A. Salazar, Angela M. Peña, María Lucrecia Luna González, Diana Marcela Cuervo-Lozada, Guillermo E. Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, Lina M. Gaviria, Mario Ernesto Correa Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza Morales, Juan Carlos Serrano Casas, Francisco Jaramillo, Rigoberto Gomez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez Veiga, David Martínez Cuadrón, Pau Montesinos. Referencia : Annals of Hematology on January 16th, 2025 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0. Derechos de uso : CC BY En línea : https://www.researchsquare.com/article/rs-5119261/v1 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002312 AC-2024-167 Archivo digital Producción Científica Artículos científicos Disponible
Título : Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor Fecha de publicación : 2024 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Abstract: Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past two decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study (NCT03955900) of patients with MM in five Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged 18 years or older diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (N=339) and private (N=682) institutions. These two groups differed in many respects, with the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio=0.84; 95% confidence interval, 0.67 to 1.04; P=0.109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : ADV-2024-013838R2 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor . - 2024.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Abstract: Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past two decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study (NCT03955900) of patients with MM in five Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged 18 years or older diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (N=339) and private (N=682) institutions. These two groups differed in many respects, with the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio=0.84; 95% confidence interval, 0.67 to 1.04; P=0.109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : ADV-2024-013838R2 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002311 AC-2024-166 Archivo digital Producción Científica Artículos científicos Disponible
Título : Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor Fecha de publicación : 2024 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625 PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39729499/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor . - 2024.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625 PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39729499/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002316 AC-2024-171 Archivo digital Producción Científica Artículos científicos Disponible
Título : Caracterización de pacientes con anemia de células falciformes en Medellín, Colombia Otros títulos : Characterization of patients with sickle cell anemia in Medellin, Colombia Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2022 Títulos uniformes : Medicina Interna de México Idioma : Español (spa) Palabras clave : Anemia de células falciformes células sanguíneas hematología hemólisis Resumen : Objetivo: Caracterizar a los pacientes con diagnóstico de anemia de células falciformes en una institución de salud de alta complejidad del área metropolitana de Medellín, Colombia. Materiales y métodos: Estudio observacional descriptivo, retrospectivo, realizado de enero de 2013 a diciembre de 2017, que incluyó pacientes con diagnóstico de anemia de células falciformes. Para el análisis de las variables cualitativas se usaron frecuencias relativas y absolutas, mientras que para las cuantitativas con distribución normal se usaron promedio, mediana, media y desviación estándar y para aquéllas con distribución no normal, mediana y rangos intercuartílicos. Resultados: Se incluyeron 74 pacientes con anemia de células falciformes, con mediana de edad al momento del diagnóstico de 3 años, predominó el sexo masculino con un 56.8% (n = 42); respecto al régimen de salud el 59.5% (n = 44) pertenecía al contributivo, seguido del subsidiado con un 25.7% (n = 19). En cuanto a las manifestaciones clínicas el 66.2% manifestó un evento vaso-oclusivo, hemólisis crónica o ambas. Conclusiones: Se evidenció que los eventos vaso-oclusivos y la anemia moderada fueron predominantes, lo que es de gran importancia para los profesionales de la salud, porque de estos eventos deriva la mayor parte de las complicaciones infecciosas y no infecciosas de los pacientes, así como los requerimientos hemodinámicos al momento de iniciar el manejo terapéutico. Mención de responsabilidad : Lina María Martínez-Sánchez, Juan Diego Villegas-Alzate, Laura Herrera-Almanza, María Antonia Correa-Saavedra, Kenny Mauricio Gálvez-Cárdenas, Alejandro Hernández-Martínez, Mabel Dahiana Roldán-Tabares, Daniela Vergara-Yanez DOI (Digital Object Identifier) : 10.24245/mim.v38i5.5897 En línea : https://medicinainterna.org.mx/article/caracterizacion-de-pacientes-con-anemia-d [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Caracterización de pacientes con anemia de células falciformes en Medellín, Colombia = Characterization of patients with sickle cell anemia in Medellin, Colombia [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2022.
Obra : Medicina Interna de México
Idioma : Español (spa)
Palabras clave : Anemia de células falciformes células sanguíneas hematología hemólisis Resumen : Objetivo: Caracterizar a los pacientes con diagnóstico de anemia de células falciformes en una institución de salud de alta complejidad del área metropolitana de Medellín, Colombia. Materiales y métodos: Estudio observacional descriptivo, retrospectivo, realizado de enero de 2013 a diciembre de 2017, que incluyó pacientes con diagnóstico de anemia de células falciformes. Para el análisis de las variables cualitativas se usaron frecuencias relativas y absolutas, mientras que para las cuantitativas con distribución normal se usaron promedio, mediana, media y desviación estándar y para aquéllas con distribución no normal, mediana y rangos intercuartílicos. Resultados: Se incluyeron 74 pacientes con anemia de células falciformes, con mediana de edad al momento del diagnóstico de 3 años, predominó el sexo masculino con un 56.8% (n = 42); respecto al régimen de salud el 59.5% (n = 44) pertenecía al contributivo, seguido del subsidiado con un 25.7% (n = 19). En cuanto a las manifestaciones clínicas el 66.2% manifestó un evento vaso-oclusivo, hemólisis crónica o ambas. Conclusiones: Se evidenció que los eventos vaso-oclusivos y la anemia moderada fueron predominantes, lo que es de gran importancia para los profesionales de la salud, porque de estos eventos deriva la mayor parte de las complicaciones infecciosas y no infecciosas de los pacientes, así como los requerimientos hemodinámicos al momento de iniciar el manejo terapéutico. Mención de responsabilidad : Lina María Martínez-Sánchez, Juan Diego Villegas-Alzate, Laura Herrera-Almanza, María Antonia Correa-Saavedra, Kenny Mauricio Gálvez-Cárdenas, Alejandro Hernández-Martínez, Mabel Dahiana Roldán-Tabares, Daniela Vergara-Yanez DOI (Digital Object Identifier) : 10.24245/mim.v38i5.5897 En línea : https://medicinainterna.org.mx/article/caracterizacion-de-pacientes-con-anemia-d [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001901 AC-2022-064 Archivo digital Producción Científica Artículos científicos Disponible 
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
PermalinkPermalink
Permalink
